ANNOUNCEMENT 08 Jan 2018

In January 2018, the European Investment Bank (EIB) signed a loan agreement with Indivumed GmbH to support the company's strategic and innovative R&D activities. The loan is guaranteed by the European Fund for Strategic Investments (EFSI).

NUMBER OF INTERVENTIONS

2

  • 2 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

The European Investment Bank, Financed Projects, INDIVUMED GLOBAL CANCER DATABASE (EGFF): http://www.eib.org/en/projects/loan/loan/20170662
The European Investment Bank, Project summary, Project No. 20170662, Project name: INDIVUMED GLOBAL CANCER DATABASE (EGFF): http://www.eib.org/en/projects/pipelines/pipeline/20170662
Indivumed, Company History: https://www.indivumed.com/about-indivumed/
European Commission (13 January 2015): The Investment Plan for Europe: Questions and Answers: http://europa.eu/rapid/press-release_MEMO-15-3223_en.htm
EIB: European Fund for Strategic Investments - Questions and Answers. Available at: http://www.eib.org/attachments/press/investment_plan_for_europe_qa_en.pdf

Inception date: 08 Jan 2018 | Removal date: open ended
Still in force

State loan

The loan agreement between the European Investment Bank (EIB) and Indivumed GmbH was signed on 8 January 2018 and has a total value of EUR 40 million (approx. USD 48 million).

More specifically, the loan will support the company's business activities mainly related to the further development of their cancer database. Indivumed GmbH is an "ISO-certified global oncology research company" providing laboratory and clinical services in the area of cancer research and therapy. The company has several partnerships with cancer clinics around the world, more than 100 biopharma partners and more than 50 oncology practices in Germany. The company has its headquarters in Germany and a subsidiary in the United States.

AFFECTED SECTORS

 
N/A

AFFECTED PRODUCTS

 
N/A
Inception date: 08 Jan 2018 | Removal date: open ended
Still in force

Loan guarantee

The EIB's loan to Indivumed GmbH signed on 8 January 2018 was issued under the European Fund for Strategic Investment (EFSI). The loan has a total value of EUR 40 million (approx. USD 48 million) and will support the company's business activities mainly related to the further development of their cancer database.

The EFSI is a joint initiative by the EIB and the European Commission to promote investment in Europe. The EIB has designated EUR 7.5 billion of its capital for lending to European projects with a higher risk profile than usually taken on by the bank. To compensate for the increased lending risk, the European Commission has agreed to fully guarantee all lending under the EFSI up to a budget of EUR 26 billion. The loan described was issued under the EFSI and thus benefits from a full guarantee through the EU budget.

EFSI support does not fall under EU State Aid rules as it is meant as a tool to address "market failures or sub-optimal investment situations". However, the investment support does include favourable conditions in the form of public assumption of risk.

As described in the European Commission's Fact Sheet from 13 January 2015: "The type of risk-financing instruments will be designed so as to take uncertainty out ("first loss protection") of as such viable projects and therefore crowd-in private sector investments. Since the EFSI will take riskier tranches in investment projects, the private sector will be able to join under more favourable conditions." Furthermore, the EIB states that "The new initiative [i.e. the EFSI] will benefit from the EIB’s strong credit standing that enables funding at favourable conditions and across maturities".

 
N/A
 
N/A